dihexa degradation pathways stability Proposed degradation pathways of the drug under different hydrolytic Degradation pathway of CyA. |

Mixed results: It is important to recognize that individual experiences with DSIP can be quite varied

Bakken Center for Spirituality & Healing, University of Minnesota, Minneapolis

The patient has established cardiovascular disease with a documented history of at least one of the following: A) Previous myocardial infarction (MI) B) Previous stroke C) Symptomatic peripheral arterial disease (PAD), evidenced by one of the following: Intermittent claudication with an ankle-brachial index (ABI) less than 0.85 at rest Peripheral arterial revascularization procedure Amputation due to atherosclerotic disease D) Prior revascularization, such as coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or angioplasty, and

The initial expected action date was March 28, 2026, but a slight delay moved the target to April 10, 2026

Dihexa activates the HGF/c-Met receptor pathway, which stimulates synaptogenesis the formation of new synaptic connections between neurons

Research programs NNMT inhibitor class development and optimization studies